August 02, 2019: Santhera Announces Closing of Licensing Transaction with Chiesi Group for Raxone® in LHON
June 25, 2019: EMA Validates Santhera’s Marketing Authorization Application for Puldysa® in Duchenne Muscular Dystrophy
June 24, 2019: UK’s MHRA renews EAMS Scientific Opinion for Santhera’s Idebenone in Duchenne Muscular Dystrophy
May 27, 2019: Santhera Submits Marketing Authorization Application to the European Medicines Agency for Puldysa® (Idebenone) in Duchenne Muscular Dystrophy
May 23, 2019: Santhera Enters into License Agreement with Chiesi Group for Raxone® in LHON Valued at up to CHF 105 Million Conference call May 23, 2019, 1300 CET
May 21, 2019: Santhera Starts Collaboration in Gene Therapy Research for Congenital Muscular Dystrophy with the Biozentrum, University of Basel, Co-Financed by Innosuisse
April 29, 2019: Santhera Reports Strong Top-line Growth for 2018 and the Successful Expansion of its Rare Disease Pipeline
April 15, 2019: Santhera to Present Long-term Efficacy Results with Idebenone in DMD at the 2019 MDA Clinical and Scientific Conference
March 28, 2019: Santhera Provides Update on Filing for Conditional Marketing Authorization in Europe for Puldysa® (Idebenone) in Duchenne Muscular Dystrophy
March 12, 2019: Santhera Completes Patient Enrollment in Phase IV Long-term Study with Raxone® for the Treatment of Leber’s Hereditary Optic Neuropathy
February 25, 2019: Santhera’s SYROS Study Shows Long-term Efficacy with Idebenone in Slowing Respiratory Function Loss in Patients with Duchenne Muscular Dystrophy
